**Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine) eModule Series for Healthcare Professionals**

**Module 2 – Knowledge Check**

1. What are the three types of meningococcal vaccine? *Select three*
	1. Polysaccharide vaccines
	2. DNA vaccines
	3. Conjugate vaccines
	4. Protein-based vaccines

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Which of the statements about *polysaccharide* meningococcal vaccines are true?
	1. They elicit long-term immunological memory
	2. They are no longer available in the United Kingdom
	3. They are manufactured using a piece of polysaccharide capsule that surrounds the *N. meningitidis* bacterium
	4. They are poorly immunogenic in children less than 2 years old

 ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. True or false. Conjugate meningococcal vaccines are manufactured by joining a piece of the polysaccharide capsule that surrounds the *N. meningitidis* bacterium to a protein carrier.

 ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. True or false: Conjugate meningococcal vaccines have demonstrated immunogenicity in infants and children less than 2 years old

 ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**ANSWERS**

1. What are the three types of meningococcal vaccine? *Select three*
	1. Polysaccharide vaccines
	2. DNA vaccines
	3. Conjugate vaccines
	4. Protein-based vaccines

 Answer: a, c and d1

1. Which of the statements about *polysaccharide* meningococcal vaccines are true?
	1. They elicit long-term immunological memory
	2. They are no longer available in the United Kingdom
	3. They are manufactured using a piece of polysaccharide capsule that surrounds the *N. meningitidis* bacterium
	4. They are poorly immunogenic in children less than 2 years old

Answer: b2, c3 and d4

1. True or false. Conjugate meningococcal vaccines are manufactured by joining a piece of the polysaccharide capsule that surrounds the *N. meningitidis* bacterium to a protein carrier.

 Answer: True5,6

1. True or false: Conjugate meningococcal vaccines have demonstrated immunogenicity in infants and children less than 2 years old

 Answer: True7

**References**

1. WHO. Immunization, Vaccines and Biologicals: Meningococcal meningitis. Available at: <http://www.who.int/immunization/diseases/meningitis/en/> Accessed June 2021.

2. Green Book. Chapter 22. Meningococcal. Available at: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/554011/Green_Book_Chapter_22.pdf> Accessed June 2021.

3. Jenner E. Salisbury D (Ed), Begg N (Ed). Immunisation against infectious disease. Bicentenary Edition. 1996. London: HMSO.

4. Goldblatt D. Immunisation and the maturation of infant immune responses. *Dev Biol Stand* 1998; 95:125-132

5. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. *Nat Rev Immunol* 2009;9(3):213–220.

6. CDC.gov Immmunology and Vaccine-Preventable Diseases. Available at: <https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/prinvac.pdf> Accessed June 2021.

7. Pfizer Limited. Nimenrix® Summary of Product Characteristics. February 2021.

